Primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) produces a cell-mediated immune response which is still present 1 year later

Veterinary Immunology and Immunopathology

Volumn 158, Issue 3-4, 2014, Pages 199-207

  Moreno, Javier ^a   Vouldoukis, Ioannis ^b   Schreiber, Paul ^c   Martin, Virginie ^c   Mcgahie, David ^c   Gueguen, Sylvie ^c   Cuisinier, Anne Marie ^c  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b INSERM   (France)

^c Virbac SA   (France)

Author keywords

Canine leishmaniasis; Cell mediated immunity; Nitric oxide; Prevention; Th1; Vaccination

Indexed keywords

FEBANTEL; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INDUCIBLE NITRIC OXIDE SYNTHASE; LEISHMANIA VACCINE; NITRIC OXIDE; PARASITE ANTIGEN; PRAZIQUANTEL; PYRANTEL EMBONATE; IMMUNOGLOBULIN G; PROTOZOON ANTIBODY;

ARTICLE; BEAGLE; BLOOD SAMPLING; BODY WEIGHT; CELLULAR IMMUNITY; CERVICAL LYMPHADENOPATHY; CLINICAL EXAMINATION; COCULTURE; CONJUNCTIVITIS; CONTROLLED STUDY; DOG; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FOLLOW UP; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; INJECTION SITE; LEISHMANIA INFANTUM; LEISHMANIASIS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION TEST; MACROPHAGE; MALE; NONHUMAN; PARASITE LOAD; PERIPHERAL BLOOD MONONUCLEAR CELL; RECTUM TEMPERATURE; SEROLOGY; SKIN IRRITATION; TH1 CELL; VACCINATION; WOUND; ANIMAL; BIOSYNTHESIS; DOG DISEASES; IMMUNOLOGY; LEISHMANIASIS, VISCERAL; TIME; VETERINARY; ZOONOSES; CLINICAL PROTOCOL; LYMPHOCYTE;

CANIS FAMILIARIS; LEISHMANIA INFANTUM;

ANIMALS; ANTIBODIES, PROTOZOAN; DOG DISEASES; DOGS; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; LEISHMANIA INFANTUM; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; MALE; TH1 CELLS; TIME FACTORS; VACCINATION; ZOONOSES;

EID: 84897058881     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2014.01.011     Document Type: Article

References (39)

1. Alexander J., Bryson K. T helper (h) 1/Th2 and Leishmania: paradox rather than paradigm. Immunol. Lett. 2005, 99:17-23.
2. Alvar J., Canavate C., Molina R., Moreno J., Nieto J. Canine leishmaniasis. Adv. Parasitol. 2004, 57:1-88.
3. Baneth G., Koutinas A.F., Solano-Gallego L., Bourdeau P., Ferrer L. Canine leishmaniosis - new concepts and insights on an expanding zoonosis: part one. Trends Parasitol. 2008, 24:324-330.
4. Barbiéri C.L. Immunology of canine leishmaniasis. Parasite Immunol. 2006, 28:329-337.
5. Bhowmick S., Ali N. Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis. PLoS ONE 2009, 4(6):e5820.
6. Bogdan C., Röllinghoff M., Diefenbach A. Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr. Opin. Immunol. 2000, 12:64-76.
7. Bourdoiseau G., Hugnet C., Gonçalves R.B., Vézilier F., Petit-Didier E., Papierok G., Lemesre J.L. Effective humoral and cellular immunoprotective responses in LiESAp-MDP vaccinated protected dogs. Vet. Immunol. Immunopathol. 2009, 128:71-78.
8. Carrillo E., Crusat M., Nieto J., Chicharro C., Thomas Mdel C., Martínez E., Valladares B., Cañavate C., Requena J.M., López M.C., Alvar J., Moreno J. Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis. Vaccine 2008, 26:1902-1911.
9. Carrillo E., Moreno J. Cytokine profiles in canine visceral leishmaniasis. Vet. Immunol. Immunopathol. 2009, 128:67-70.
10. Day M.J. Immunoglobulin G subclass distribution in canine leishmaniosis: a review and analysis of pitfalls in interpretation. Vet. Parasitol. 2007, 147:2-8.
11. Day M.J. Immune system development in the dog and cat. J. Comp. Pathol. 2007, 137(Suppl. 1):S10-S15.
12. Dye C. The logic of visceral leishmaniasis control. Am. J. Trop. Med. Hyg. 1996, 55:125-130.
13. Gramiccia M., Gradoni L. The current status of zoonotic leishmaniases and approaches to disease control. Int. J. Parasitol. 2005, 35:1169-1180.
14. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal. Biochem. 1982, 126:131-138.
15. Heinzel F.P., Sadick M.D., Holaday B.J., Coffman R.L., Locksley R.M. Reciprocal expression of interferon γ or interleukin 4 during the resolution or progression of murine leishmaniasis. J. Exp. Med. 1989, 169:59-72.
16. Holzmuller P., Cavaleyra M., Moreaux J., Kovacic R., Vincendeau P., Papierok G., Lemesre J.L. Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis. Vet. Immunol. Immunopathol. 2005, 106:247-257.
17. Maroli M., Rossi L., Baldelli R., Capelli G., Ferroglio E., Genchi C., Gramiccia M., Mortarino M., Pietrobelli M., Gradoni L. The northward spread of leishmaniasis in Italy: evidence from retrospective and ongoing studies on the canine reservoir and phlebotomine vectors. Trop. Med. Int. Health 2008, 13:256-264.
18. McMahon-Pratt D., Alexander J. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?. Immunol. Rev. 2004, 201:206-224.
19. Moreno J., Nieto J., Chamizo C., González F., Blanco F., Barker D.C., Alva J. The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy. Vet. Immunol. Immunopathol. 1999, 71:181-195.
20. Moreno J., Alvar J. Canine leishmaniasis: epidemiological risk and the experimental model. Trends Parasitol. 2002, 18(9):399-405.
21. Moreno J., Vouldoukis I., Martin V., Mcgahie D., Cuisinier A.M., Gueguen S. Use of a LiESP/QA-21 vaccine (CaniLeish) stimulates an appropriate Th1-dominated Cell-mediated immune response in dogs. PLoS Negl. Trop. Dis. 2012, 6(6):e1683.
22. Nacy C.A., Nelson B.J., Meltzer M.S., Green S.J. Cytokines that regulate macrophage production of nitrogen oxides and expression of antileishmanial activities. Res. Immunol. 1991, 142:573-576.
23. Neogy A.B., Vouldoukis I., da Costa J.M., Monjour L. Exploitation of parasite-derived antigen in therapeutic success against canine visceral leishmaniosis. Vet. Parasitol. 1994, 54:367-373.
24. Noël W., Raes G., Hassanzadeh Ghassabeh G., De Baetselier P., Beschin A. Alternatively activated macrophages during parasite infections. Trends Parasitol. 2004, 20:126-133.
25. Otranto D., Dantas-Torres F. The prevention of canine leishmaniasis and its impact on public health. Trends Parasitol. 2013, 29(7):339-345.
26. Perez L.E., Chandrasekar B., Saldarriaga O.A., Zhao W., Arteaga L.T., Travi B.L., Melby P.C. Reduced nitric oxide synthase 2 (NOS2) promoter activity in the Syrian hamster renders the animal functionally deficient in NOS2 activity and unable to control an intracellular pathogen. J. Immunol. 2006, 176:5519-5528.
27. Reis A.B., Giunchetti R.C., Carrillo E., Martins-Filho O.A., Moreno J. Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis. Trends Parasitol. 2010, 26:341-349.
28. Resende M., Moreira D., Augusto J., Cunha J., Neves B., Cruz M.T., Estaquier J., Cordeiro-da-Silva A., Silvestre R. Leishmania-infected MHC class IIhigh dendritic cells polarize CD4+ T cells toward a nonprotective T-bet+ IFN-γ+ IL-10+ phenotype. J. Immunol. 2013, 191(1):262-273.
29. Santos-Gomes G.M., Rosa R., Leandro C., Cortes S., Romão P., Silveira H. Cytokine expression during the outcome of canine experimental infection with Leishmania infantum. Vet. Immunol. Immunopathol. 2002, 88:21-30.
30. Sharma U., Singh S. Immunobiology of leishmaniasis. Indian J. Exp. Biol. 2009, 47:412-423.
31. Solano-Gallego L., Morell P., Arboix M., Alberola J., Ferrer L. Prevalence of Leishmania infantum infection in dogs living in an area of canine leishmaniasis endemicity using PCR on several tissues and serology. J. Clin. Microbiol. 2001, 39:560-563.
32. Solano-Gallego L., Koutinas A., Miró G., Cardoso L., Pennisi M.G., Ferrer L., Bourdeau P., Oliva G., Baneth G. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. Vet. Parasitol. 2009, 165:1-18.
33. Strauss-Ayali D., Baneth G., Jaffe C.L. Splenic immune responses during canine visceral leishmaniasis. Vet. Res. 2007, 38:547-564.
34. Vouldoukis I., Riveros-Morenot V., Dugas B., Ouaaz F., Becherel P., Debré P., Moncada S., Mossalayi M.D. The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after ligation of the FccRII/CD23 surface antigen. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:7804-7808.
35. Vouldoukis I., Drapier J.C., Nüssler A.K., Tselentis Y., Da Silva O.A., Gentilini M., Mossalayi D.M., Monjour L., Dugas B. Canine visceral leishmaniasis: successful chemotherapy induces macrophage antileishmanial activity via the l-arginine nitric oxide pathway. Antimicrob. Agents Chemother. 1996, 40:253-256.
36. Vouldoukis I., Bécherel P.A., Riveros-Moreno V., Arock M., da Silva O., Debré P., Mazier D., Mossalayi M.D. Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation. Eur. J. Immunol. 1997, 27:860-865.
37. Vouldoukis I., Rougier S., Dugas B., Pino P., Mazier D., Woehrlé F. Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimonate and sodium stibogluconate. Vet. Parasitol. 2006, 135:137-146.
38. Wanasen N., Soong L. l-arginine metabolism and its impact on host immunity against Leishmania infection. Immunol. Res. 2008, 41:15-25.
39. Zafra R., Jaber J.R., Pérez-Ecija R.A., Barragán A., Martínez-Moreno A., Pérez J. High iNOS expression in macrophages in canine leishmaniasis is associated with low intracellular parasite burden. Vet. Immunol. Immunopathol. 2008, 123:353-359.